Shares of specialty generic pharmaceutical manufacturer Teligent (NASDAQ: TLGT) dropped as much as 46% today after investors digested the company’s third-quarter 2017 results. Operations appeared to have slowed after a strong first half of the year. That forced management to lower its full-year 2017 financial guidance for revenue and gross margin.